Sanofi India Declares Interim Dividend of ₹75/Share; Q3 Profit Rises 54% to ₹116.7 Crore
Sanofi India Limited declared an interim dividend of ₹75 per equity share for FY26. The company reported a 54% year-on-year growth in Profit After Tax (PAT) for Q3'26. Net sales grew by 4% in Q3'26, driven by a 9% increase in the diabetes portfolio.
The declaration of an interim dividend and strong financial performance are significant events that directly impact shareholders and the company's financial standing.
The company reported strong financial results with profit growth and declared an interim dividend, indicating positive performance and shareholder returns.
Sanofi India Limited announced its unaudited financial results for the quarter and nine months ended September 30, 2026. The Board of Directors, in a meeting held on October 29, 2026, approved these results.
The company reported strong performance with profits before tax and exceptional items rising 22% to ₹158 crore, compared to ₹130 crore in the third quarter of 2025. Profit before tax as a percentage of net sales improved to 34% in Q3 2026, up from 29% in Q3 2025. This improvement was attributed to a favorable product mix, a one-off reversal of provisions, and disciplined cost management.
In a significant announcement, the Board declared an interim dividend of ₹75 per equity share of face value ₹10 for the financial year 2026. The company has fixed Thursday, November 5, 2026, as the record date for the payment of this interim dividend. The financial results will be published in newspapers as per regulatory requirements.
The company's diabetes portfolio showed a 9% growth in Q3 '26, maintaining Sanofi's leadership in the Diabetes Injectable segment with a 55% market share. Domestic net sales grew by 2% and total net sales by 4% compared to the third quarter of 2025. Export sales also delivered strong double-digit growth.
The Board meeting commenced at 2:30 p.m. and concluded at 4:45 p.m. on October 29, 2026.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.